Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib in Relapsed/Refractory Multiple Myeloma
NCT05549973Phase 1Unknown
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Sep 2022
- Primary completion
- Jul 2023
- Countries
- 1
01
Overview
Phase 1, open-label trial of anlotinib in multiple myeloma (MM), sponsored by Institute of Hematology and Blood Diseases Hospital. Status: unknown.
02
Drugs
anlotinib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05549973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05549973.